Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Dec;14(1):2469375.
doi: 10.1080/2162402X.2025.2469375. Epub 2025 Feb 21.

Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

Anet Greib  1 , Songzhu Zhao  2 , Michelle Ploch  3 , Jonathan Henricks  4 , Robert Easterling  1 , Meghana Moodabagil  4 , Gabrielle Lopez  5 , Mingjia Li  5 , Evelyn G Goodyear  6 , John Sharp  5 , Asrar Alahmadi  5 , Jacob Kaufman  5 , Regan Memmott  5 , Kai He  5 , Peter Shields  5 , David P Carbone  5 , Gregory A Otterson  5 , Carolyn J Presley  5 , Lai Wei  2 , Dwight H Owen  5   7 , Kevin Ho  3
Affiliations

Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients

Anet Greib et al. Oncoimmunology. 2025 Dec.

Abstract

Immune checkpoint inhibitors (ICIs) are first line treatment for advanced lung cancer. Tobacco use is a shared risk factor for lung cancer and chronic obstructive pulmonary disease (COPD). Although many patients with COPD and lung cancer receive ICIs, the impact of ICIs on COPD is unknown. Here, we evaluated whether ICI treatment was associated with increased COPD disease burden. We conducted a retrospective cohort study of lung cancer patients with and without preexisting COPD who received ICIs from 2011-2021 at The Ohio State University (OSU). For all patients, number of steroid courses and respiratory related hospitalizations were recorded. For those with COPD, COPD medications were collected at and after ICI initiation. Pulmonary function tests, COPD exacerbations, and COPD-related hospitalizations were compared before and after ICI treatment. Linear and generalized mixed models were used to account for potential confounders of worsening COPD. Among 1083 lung cancer patients who received ICIs, 585 (54.0%) had pre-ICI COPD. Patients with COPD were prescribed more COPD medications (3 [1, 4] vs 1 [0, 3], p < 0.001), had more COPD exacerbations (38.3% vs 25.8%, p < 0.001), and more COPD-related hospitalizations (27.9% vs 16.9%, p < 0.001) after ICI initiation compared to before. These findings persisted after multivariable analysis controlling for patients who received chemotherapy or chemoradiation within 12 months of ICI initiation, cancer type, age, BMI, sex, smoking status, type of ICI, and number of ICI doses (p < 0.001). This is a comprehensive study that describes lung cancer patients with COPD treated with ICIs have increased COPD disease burden after ICI initiation.

Keywords: Chronic obstructive pulmonary disease (COPD); immune checkpoint inhibitors (ICI); lung cancer.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Comparing pulmonary function tests, COPD exacerbations, and COPD-Related hospitalizations before and after ICI treatment.
Figure 2.
Figure 2.
Flow chart of patients in study.
Figure 3.
Figure 3.
COPD disease burden before and after ICI Treatment.
See this image and copyright information in PMC

References

    1. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1). doi: 10.1038/S41467-020-17670-Y. - DOI - PMC - PubMed
    1. Onoi K, Chihara Y, Uchino J, Shimamoto T, Morimoto Y, Iwasaku M, Kaneko Y, Yamada T, Takayama K. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med. 2020;9(5):1362. doi: 10.3390/JCM9051362. - DOI - PMC - PubMed
    1. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375(19):1823–8. doi: 10.1056/nejmoa1606774/supplfile/nejmoa1606774disclosures.pdf. - DOI - PubMed
    1. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377(20):1919–1929. doi: 10.1056/nejmoa1709937/suppl_file/nejmoa1709937_disclosures.pdf. - DOI - PubMed
    1. Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, et al. First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi: 10.1056/nejmoa1809064/suppl_file/nejmoa1809064_data-sharing.pdf. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources